Navigation Links
Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer
Date:11/5/2011

oss Corp. has been collaborating with Jennerex in Korea since 2006 to jointly conduct the Phase 1 and 2 clinical trials in patients with liver cancer. Additional information about Green Cross Corp. is available on the internet at www.greencross.com.

Lee's Pharmaceutical Holdings Limited is a public biopharmaceutical company with over 16 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets nine products. Lee's Pharma focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various U.S. and European companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.  Additional information about Lee's Pharma is available on the internet at www.leespharm.com.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in an international, randomized Phase 2b clinical trial (TRAVERSE) in patients with advanced primary liver cancer who have failed sorafenib therapy. In addition, JX-594 is being tested in the same patient population in combination with sorafenib. JX-594 is also in a Phase 1 clinical trial in patients with treatment-refractory colorectal cancer. Published studies designed to establish optimal dose levels and th
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
2. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
3. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
4. Jennerex Closes $5 Million First Tranche of Series C Financing
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
7. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
8. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
9. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
10. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
11. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... ROCKLAND, Massachusetts , September 19, 2014 ... with the 53rd European Society for Paediatric Endocrinology (ESPE) ... advancement of science and medical research in the field ... of Merck KGaA, Darmstadt, Germany , ... Growth Innovation (GGI) for 2014. The awards were announced ...
(Date:9/18/2014)... HealthTronics, Inc ., a ... products and services, announced that a poster related ... versus external beam radiotherapy (EBRT) is being presented ... Association (MAAUA) Annual Meeting in Baltimore, Maryland September ... Cryosurgery and External Beam Radiation as Treatments for ...
(Date:9/18/2014)... Mass. (PRWEB) September 18, 2014 A ... of an MRI scanner is currently being tested as ... and Women's Hospital in Boston with the aim of ... images, can make prostate cancer biopsies faster, more accurate, ... novel system also has the potential to deliver prostate ...
(Date:9/18/2014)... Bryan-College Station, Texas (PRWEB) September 18, 2014 ... University System Chancellor John Sharp, Texas A&M Health ... from the U.S. Department of Health and Human ... GSK today dedicated a national pandemic influenza vaccine ... will serve as an anchor for the Texas ...
Breaking Biology Technology:EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... the Hyatt Regency Cambridge, ... Massachusetts, ... leading marketplace for expertise, and the Biotechnology Industry,Organization (BIO) announced an ... venture investment community,registered to attend the BIO National Venture Conference, with ...
... Executive Positions, WITTEN, Germany, April 8 Sangui ... its,fiscal year ended June 30, 2006, on April 3, ... with the SEC the company almost tripled its sales,of ... level. In,FY 2006, Sangui yielded sales of approximately USD ...
... DUBLIN, Calif., April 8, 2008 Microchip,Biotechnologies, Inc. ... Centre,for DNA Barcoding (CCDB), at the Biodiversity Institute ... participant to join MBI,s early,access program for the ... is the,first fully automated and integrated system for ...
Cached Biology Technology:Gerson Lehrman Group Extends Partnership With BIO to Provide Scientific Expertise for the First Annual BIO National Venture Conference 2Gerson Lehrman Group Extends Partnership With BIO to Provide Scientific Expertise for the First Annual BIO National Venture Conference 3Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses 2Sangui BioTech International, Inc., Reports Sales Increase, Continued Losses 3Canadian Centre for DNA Barcoding to Participate in Microchip Biotechnologies Early Access Program for Microchip-Based DNA Sample Preparation and Cycle Sequencing 2
(Date:9/18/2014)... foliage season that prompts millions of Americans to undertake jaunts ... possibly last a little longer within a century, according to ... in some areas of the United States as summer temperatures ... the journal Global Ecology and Biogeography . For instance, ... the state tree of New Hampshire could change color ...
(Date:9/18/2014)... tiny strands of nucleic acid that contain instructions for ... data, our DNA is copied into RNA molecules, which ... in our cells. , Several years ago, scientists ... other known RNAs, this molecule is circular, and was ... has been known about how they are produced. Moreover, ...
(Date:9/18/2014)... 2014 -- Arizona turned its newborn screening program into a ... months, earning it the first-ever Newborn Screening Quality Award from ... presented Will Humble, M.P.H., Arizona,s Department of Health Services director, ... Humble established a policy of full transparency for the length ... samples to the lab for analysis, and set a target ...
Breaking Biology News(10 mins):Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3
... long thought to have fully recovered from whaling, were once ... according to a report to be published September 10 in ... Todays population of more than 22,000 gray whales has successfully ... now the most abundant whale on the North American west ...
... consultant to UNESCO and a former Administrator of the National ... Stevens Institute of Technology, Sept. 26, titled, Global Warming and ... The talk will be delivered at Stevens Babbio Center for ... Babbio Center is located on the Stevens campus in Hoboken, ...
... of Energy,s Brookhaven National Laboratory have developed new ways ... oxide, a material used in a variety of industrial ... materials may lead to improved catalysts for hydrogen production, ... research is published in two papers now available online, ...
Cached Biology News:Gray whales a fraction of historic levels, genetic research says 2Global Warming and the Habitability of Planet Earth, Sept. 26 2Tiny tubes and rods show promise as catalysts, sunscreen 2
Recombinant Mouse TGF-beta RII/(human) Fc Chimera, CF...
Recombinant Mouse Noggin...
... Antibody Sampler Kit Kit Includes: ... 40 ul Histone Deacetylase 3 (HDAC3) Antibody, ... (HDAC4) Antibody, Catalog #2072, 40 ul Histone ... ul Histone Deacetylase 6 (HDAC6) Antibody, Catalog ...
An instrument that delivers an accurate and uniform amount of light energy to cells to photoactivate csiRNA products....
Biology Products: